Trial intelligence / Profile preview

Phase II randomized trial of MK-5172 + MK-8742 with or without ribavirin in treatment-naive chronic hepatitis C genotype 1

2012-003354-89Phase 2Terminated

Sponsor

Merck & Co.

Start

Dec 2012

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Countries

1